NovoCure Limited
NVCR
|
$12.09
0.33%
0.33%
850K
|
Health Technology
(0.0% 1d) (-11.6% 1m) (-80.5% 1y) (0.0% 2d) (0.0% 3d) (-5.3% 7d) (47.34% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,300,960,276
http://www.novocure.com
Sec Filling | Patents | 782 employees
(JE) NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
cancer t-cell treatment ceiling eletrical
add to watch list Paper trade email alert is off
Press-releases
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -4.16%
H: 1.07%
C: -2.28%
association cancer pancreatic tumor research preclinical for meeting
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Published: 2024-03-11 (Crawled : 12:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 1.09%
H: 1.02%
C: -4.37%
presentation best
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Published: 2024-02-22 (Crawled : 18:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 8.71%
H: 0.12%
C: -10.25%
company year update financial results
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Published: 2024-01-18 (Crawled : 12:30) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 4.19%
H: 21.15%
C: 12.06%
fda lung cancer cell application therapy
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 1.25%
H: 4.12%
C: -2.06%
trial glioblastoma
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 0.0%
H: 3.78%
C: 2.43%
growth
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
Published: 2023-11-21 (Crawled : 19:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -1.39%
H: 2.12%
C: 1.75%
conference
Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
Published: 2023-11-10 (Crawled : 15:30) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -0.17%
H: 0.17%
C: -2.88%
tumor meeting
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 6.62%
H: 2.29%
C: -0.06%
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 8.3%
H: 0.02%
C: -2.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.57%
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: -6.94%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.29%
H: 0.21%
C: -0.48%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.27%
H: 0.14%
C: -3.34%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 7.35%
H: 0.44%
C: -2.18%
results
Novocure Reports Third Quarter 2023 Financial Results
Published: 2023-10-26 (Crawled : 14:00) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 2.84%
H: 0.0%
C: -10.08%
financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10